Please use this identifier to cite or link to this item:
HOST-DIRECTED THERAPIES IN PULMONARY TUBERCULOSIS: UPDATES ON ANTI-INFLAMMATORY DRUGS
Mycobacterium tuberculoses
Terapia adjuvante
imunoterapias
Author
Affilliation
Abstract
Tuberculosis (TB) is a lethal disease and remains one of the top ten causes of mortality by an infectious disease worldwide. It can also result in significant morbidity related to persistent inflammation and tissue damage. Pulmonary
TB treatment depends on the prolonged use of multiple drugs ranging from 6 months for drug-susceptible TB to 6–20 months in cases of multi-drug resistant disease, with limited patient tolerance resulting from side effects.
Treatment success rates remain low and thus represent a barrier to TB control. Adjunct host-directed therapy (HDT) is an emerging strategy in TB treatment that aims to target the host immune response to Mycobacterium
tuberculosis in addition to antimycobacterial drugs. Combined multi-drug treatment with HDT could potentially result in more effective therapies by shortening treatment duration, improving cure success rates and reducing
residual tissue damage. This review explores the rationale and challenges to the development and implementation of HDTs through a succinct report of the medications that have completed or are currently being evaluated in
ongoing clinical trials.
Keywords in Portuguese
Terapia dirigida pelo hospedeiroMycobacterium tuberculoses
Terapia adjuvante
imunoterapias
Share